Therapeutics;
Digital health (pure digital, no wet biology or chem);
Uncapped convertible notes
Dr. Jenny Rooke is the Founder and serves as Managing Director at Genoa Ventures. She is an early-stage venture capital investor. She is the Founder and serves as a Managing Director at 5 Prime Ventures. She also served as a Venture Partner at F-Prime Capital Partners (healthcare) and Anterra Capital (agriculture). She brings a combination of strategy, operating, and investing experience to her work with early stage life science companies, specializing in research tools, diagnostics, and synthetic biology. Jenny's investing experience includes roles in the Bill & Melinda Gates Foundation's Global Health Discovery group, and at F-Prime Capital, where she served her Kauffman Fellowship. Dr. Rooke held multiple executive positions at U.S. Genomics, a venture-backed biotech start-up advancing single molecule detection technologies for diagnostics, biodefense, and research. Previously, Dr. Rooke was a management consultant with McKinsey & Co., where she advised leading pharmaceutical and biotech companies on business strategy. Dr. Rooke earned her Ph.D. in genetics from Yale University and her B.S. in physics from Georgia Tech. She is also a Board Member at Intabio.
Varun Gupta
Investing in Software (Web Marketplace Saas..) &b...
Bio + Health Tech VC supporting Founder-led startups. 3x Founder. 12x exits in life sciences.
Shahram Seyedin-Noor is the Founder and serves as General Partner at Civilization Ventures. Seyedin-Noor is a Co-Founder at Rgenix and previously served as an Advisor. He was previously its Executive Chairman and Chief Business Officer. Prior to Rgenix, Seyedin-Noor was a founding executive at NextBio, a pioneer in genomics data analysis and personalized medicine. NextBio was acquired by Illumina in 2013 (NASDAQ: ILMN). Seyedin-Noor helped grow NextBio into a profitable leader in the life sciences with millions in revenues from top-tier customers such as Merck, Celgene, J&J, Regeneron, Pfizer and nearly every other major biotech/pharma company. He is also an angel investor in various innovative healthcare startups, including Avantome (acq. by Illumina), Bina Technologies (acq. by Roche), Counsyl and Omada Health, among others. Prior to founding Civilization Ventures, Shahram was an entrepreneur and angel investor. Shahram is a founding executive in several life sciences companies, including Rgenix, a biotech company with first-in-class therapeutics for cancer, now in Phase 1 clinical trials. Prior to Rgenix, he was founding CFO and VP of Corporate Development at NextBio, a genomics big data analytics pioneer acquired by Illumina in 2013. Shahram is also a seed investor in category-defining startups such as Omada Health and Counsyl. Shahram began his career in Silicon Valley as startup counsel at Wilson Sonsini Goodrich & Rosati, and later as a high tech investment banker at Goldman Sachs. Shahram earned his JD from Harvard Law School, where he was elected Editor-in-Chief of the Harvard International Law Journal, and obtained a BA in Economics from Pomona College.
Robert Lacher
Investing in Software (Web Marketplace Saas..) &b...
Building & Investing in Recurring Revenue, Highly Scalable Businesses
Partner Underdog Labs Seed Fund
Entrepreneur, adventurer.
Linked In Description:
Serial entrepreneur with interest scalable businesses with recurring revenue models. Also interested in businesses with social mission. Specialties: Internet, startups, strategic partnerships, business development, business models, consumer membership models, recurring revenue models
Zach Weinberg
Investing in Software (Web Marketplace Saas..) &b...
How to connect with Angel Investors in the Pharmaceutical industry?
In the Pharmaceutical & Medicine industry, angel investors such as Esther Dyson, Vinod Khosla, and Steve Jurvetson are prominent figures. These investors focus on startups offering innovative solutions in drug development, biotechnology, and medical research. Esther Dyson, an entrepreneur and investor, invests in pharmaceutical startups that leverage technology to advance medical research and improve patient outcomes. Vinod Khosla, founder of Khosla Ventures, looks for companies that provide groundbreaking pharmaceutical solutions and therapies. Steve Jurvetson, a co-founder of Future Ventures, seeks out startups with strong scientific foundations and significant market potential. To connect with these investors, attend pharmaceutical conferences, biotech expos, and networking events such as BIO International Convention, JP Morgan Healthcare Conference, and CPhI Worldwide. Utilize platforms like AngelList and LinkedIn to identify and reach out to potential investors. When pitching, emphasize how your pharmaceutical solution addresses key challenges, such as improving drug efficacy, enhancing patient care, or advancing medical research. Highlight any traction you’ve gained, such as partnerships with research institutions, successful clinical trials, or regulatory approvals. Building relationships through initial informal meetings or discussions at industry panels can help establish trust with these investors. Demonstrating the impact of your technology through case studies or clinical results can also add credibility. Personalize your outreach by referencing the investor’s previous investments and explaining how your venture aligns with their interests. Demonstrating a sustainable business model with clear revenue streams, such as drug sales, licensing, or research grants, will further strengthen your pitch. Leveraging endorsements or case studies from pharmaceutical experts can also enhance your credibility.
Case Studies: Successful Funding Rounds with Angel Investors on Angels Partners
Exotic Orange & Angels Partners: Turning Financial Simplicity Into Investment Success
